DexCom, Inc. (DXCM) EVP Sells $389,400.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 6,490 shares of DexCom stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $60.00, for a total value of $389,400.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Andrew K. Balo also recently made the following trade(s):

  • On Monday, September 11th, Andrew K. Balo sold 3,244 shares of DexCom stock. The shares were sold at an average price of $72.27, for a total value of $234,443.88.

Shares of DexCom, Inc. (NASDAQ DXCM) opened at $58.02 on Friday. DexCom, Inc. has a 1-year low of $42.62 and a 1-year high of $88.80. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.

Several equities research analysts have recently issued reports on the company. Canaccord Genuity reiterated a “buy” rating and set a $90.00 price target on shares of DexCom in a report on Tuesday, August 22nd. ValuEngine upgraded DexCom from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub upgraded DexCom from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Barclays assumed coverage on DexCom in a report on Friday, September 15th. They set an “equal weight” rating and a $76.00 price target for the company. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $90.00 price target (down from $105.00) on shares of DexCom in a report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $70.69.

Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC increased its position in DexCom by 9.9% in the 2nd quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock worth $791,799,000 after buying an additional 978,898 shares during the period. Janus Henderson Group PLC increased its position in DexCom by 29.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock worth $431,510,000 after buying an additional 1,991,094 shares during the period. Vanguard Group Inc. increased its position in DexCom by 3.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock worth $498,963,000 after buying an additional 224,808 shares during the period. BlackRock Inc. increased its position in DexCom by 5.5% in the 2nd quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock worth $321,232,000 after buying an additional 230,542 shares during the period. Finally, Brown Advisory Inc. increased its position in DexCom by 57.2% in the 3rd quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after buying an additional 1,515,134 shares during the period.

TRADEMARK VIOLATION NOTICE: “DexCom, Inc. (DXCM) EVP Sells $389,400.00 in Stock” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/03/dexcom-inc-dxcm-evp-sells-389400-00-in-stock.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

What are top analysts saying about DexCom Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DexCom Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit